Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations

Pekarek, Leonel; Torre-Escuredo, Basilio De la; Fraile-Martínez, Óscar; García-Montero, Cielo; Sáez, Miguel A.; Cobo-Prieto, David; Guijarro, Luis; Saz, José Vicente; Castro-Martinez, Patricia De; Torres-Carranza, Diego; Pekarek, Tatiana; Carrera, Ana C.; Álvarez-Mon, Melchor; Ortega, Miguel Á.

doi:10.3390/ijms232314939

Cited by 9 publications

(10 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chromosomal rearrangement of anaplastic lymphoma kinase (ALK) was first described in 2007 in anaplastic large cell lymphomas, and Soda et al reported that it occurs in ~7% of patients with NSCLC [ 68 ]. It is much more frequent in adenocarcinomas than in squamous or large cell tumors, where its presence is very rare [ 69 ].…”

Section: Targeted Therapy In Nsclcmentioning

confidence: 99%

Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer

Ortega

Pekarek

Navarro

et al. 2023

JPM

Self Cite

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the most frequent form of lung cancer and represents a set of histological entities that have an ominous long-term prognosis, for example, adenocarcinoma, squamous carcinoma and large cell carcinoma. Both small cell and non-small cell lung cancer are the main causes of oncological death and the oncological diseases with the highest incidence worldwide. With regard to clinical approaches for NSCLC, several advances have been achieved in diagnosis and treatment; the analysis of different molecular markers has led to the development of new targeted therapies that have improved the prognosis for selected patients. Despite this, most patients are diagnosed in an advanced stage, presenting a limited life expectancy with an ominous short-term prognosis. Numerous molecular alterations have been described in recent years, allowing for the development of therapies directed against specific therapeutic targets. The correct identification of the expression of different molecular markers has allowed for the individualization of treatment throughout the disease course, expanding the available therapeutic arsenal. The purpose of this article is to summarize the main characteristics of NSCLC and the advances that have occurred in the use of targeted therapies, thus explaining the limitations that have been observed in the management of this disease.

show abstract

Section: Targeted Therapy In Nsclcmentioning

confidence: 99%

Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer

Ortega

Pekarek

Navarro

et al. 2023

JPM

Self Cite

View full text Add to dashboard Cite

show abstract

“…In Table 1 , we summarize the main miRNAs altered in the cell cycle and the type of cancer in which they appear. Because of this, an increasing number of works are studying their potential applications as translational biomarkers for use in prognosis or as predictive responses to the therapy received, as well as possible therapeutic targets to improve the clinical management of these patients [ 38 , 47 ].…”

Section: Role Of Micrornas In Cell Cyclementioning

confidence: 99%

An Overview of the Role of MicroRNAs on Carcinogenesis: A Focus on Cell Cycle, Angiogenesis and Metastasis

Pekarek

Torres-Carranza

Fraile-Martínez

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

In recent years, the importance of epigenetic markers in the carcinogenesis of different malignant neoplasms has been demonstrated, also demonstrating their utility for understanding metastatic spread and tumor progression in cancer patients. Among the different biomarkers, microRNAs represent a set of non-coding RNAs that regulate gene expression, having been involved in a wide variety of neoplasia acting in different oncogenic pathways. Both the overexpression and downregulation of microRNAs represent a complex interaction with various genes whose ultimate consequence is increased cell proliferation, tumor invasion and interaction with various driver markers. It should be noted that in current clinical practice, even though the combination of different microRNAs has been shown to be useful by different authors at diagnostic and prognostic levels, there are no diagnostic kits that can be used for the initial approach or to assess recurrences of oncological diseases. Previous works have cited microRNAs as having a critical role in several carcinogenic mechanisms, ranging from cell cycle alterations to angiogenesis and mechanisms of distant metastatic dissemination. Indeed, the overexpression or downregulation of specific microRNAs seem to be tightly involved in the modulation of various components related to these processes. For instance, cyclins and cyclin-dependent kinases, transcription factors, signaling molecules and angiogenic/antiangiogenic products, among others, have been recognized as specific targets of microRNAs in different types of cancer. Therefore, the purpose of this article is to describe the main implications of different microRNAs in cell cycle alterations, metastasis and angiogenesis, trying to summarize their involvement in carcinogenesis.

show abstract

“…As cells inside the bone begin to divide uncontrollably, osteosarcoma occurs and can be extremely aggressive and has distal metastatic properties. 5,6 Apoptosis, autophagy, necrosis, and pyroptosis are regular forms of cell death. 7 Ferroptosis, a new form of cell death, is mediated by intracellular iron and is clearly distinguished from other forms of cell death forms.…”

Section: Introductionmentioning

confidence: 99%

Curcumin induces ferroptosis and apoptosis in osteosarcoma cells by regulating Nrf2/GPX4 signaling pathway

Yuan,

Fan,

Zhu

et al. 2023

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Curcumin, an antitumor agent, has been shown to inhibit cell growth and metastasis in osteosarcoma. However, there is no evidence of curcumin and its regulation of cell ferroptosis and nuclear factor E2–related factor 2 (Nrf2)/glutathione peroxidase 4 (GPX4) signaling pathways in osteosarcoma. This study aimed to investigate the effects of curcumin on osteosarcoma both in vitro and in vivo. To explore the effects and mechanisms of curcumin on osteosarcoma, cells (MNNG/HOS and MG-63) and xenograft mice models were established. Cell viability, cell apoptosis rate, cycle distribution, cell migration, cell invasion, reactive oxygen species, malonaldehyde and glutathione abilities, and protein levels were detected by cell counting kit-8, flow cytometry, wound healing, transwell assay, respectively. Nrf2 and GPX4 expressions were detected using an immunofluorescence assay. Nrf2/GPX4-related protein levels were detected using western blotting. The results showed that curcumin effectively decreased cell viability and increased apoptosis rate. Meanwhile, curcumin inhibited tumor volume in the xenograft model, and Nrf2/GPX4-related protein levels were also altered. Interestingly, the effects of curcumin were reversed by liproxstatin-1 (an effective inhibitor of ferroptosis) and bardoxolone-methyl (an effective activator of Nrf2). Our results indicate that curcumin has therapeutic effects on osteosarcoma cells and a xenograft model by regulating the expression of the Nrf2/GPX4 signaling pathway.

show abstract

Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations

Cited by 9 publications

References 68 publications

Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer

Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer

An Overview of the Role of MicroRNAs on Carcinogenesis: A Focus on Cell Cycle, Angiogenesis and Metastasis

Curcumin induces ferroptosis and apoptosis in osteosarcoma cells by regulating Nrf2/GPX4 signaling pathway

Contact Info

Product

Resources

About